 PER has a long t½, averaging 105 hours  Study design is critical for interpreting PK data of compounds with a long t½  With a short-term dosing design, ketoconazole had a negligible effect on PER PK  A larger effect is predicted if co-administration continues for a longer period Results: Single oral doses of 1 mg perampanel and once-daily oral doses of ketoconazole 400 mg were safe and well tolerated. Maximum perampanel plasma concentration (C max ) and time to C max showed no apparent differences when perampanel was administered alone versus with ketoconazole. Ketoconazole 3 co-administration with resulted in an approximate 20% increase in perampanel AUC (P<0.001). This increase, although statistically significant, was a <2.0-fold AUC change and alone would suggest a modest effect of ketoconazole. To further explore these results, DDI simulations were performed to query the findings and test additional study conditions. Using the actual trial conditions of Study 005, the simulations also predicted an AUC ratio increase <2-fold, providing verification of the simulation assumptions and the modest effect of ketoconazole for 10 days. Simulations further suggested that an interaction effect of ketoconazole on perampanel exposure (>2-fold) of potential clinical significance could be predicted when using larger doses of ketoconazole (e.g., 200 mg every 6 hours) coadministered for a greater time period (e.g., 30 days), with AUC ratio as high as 3.36. Additionally, simulations suggested that a significant interaction with co-administration of perampanel and an inhibitor more potent than ketoconazole (such as itraconazole) could not be ruled out.
ABSTRACT
Objectives: Perampanel, a selective, noncompetitive AMPA receptor antagonist, is indicated as adjunctive therapy for the treatment of partial seizures with or without secondarily generalized seizures and primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. In vitro studies and Phase I trials indicate that perampanel is metabolized almost exclusively by CYP3A, with an elimination half-life (t 1/2 ) averaging approximately 105 hours. Understanding of pharmacokinetic (PK) interactionsenzyme inhibition or induction-and anticipating their occurrence are important for management of patients with epilepsy. Here we report PK results from a Phase I drug-drug interaction (DDI) study (Study 005) combining perampanel with the CYP3A inhibitor ketoconazole, as well as supplementary in silico predictions further exploring this interaction.
Methods: A Phase I, randomized, open-label, two-period, two-treatment, two-way crossover study was conducted in 26 healthy adult male volunteers. Subjects were randomized to 1 of 2 treatment sequences.
In one period, subjects received a single 1-mg fasting dose of perampanel (Day 1); in the other period, subjects received ketoconazole 400 mg once daily for 10 days with a single 1-mg perampanel dose while fasting (Day 3). Blood samples were drawn at multiple time points up to 288 hours after the perampanel dose. Pharmacokinetic parameters of perampanel were calculated by noncompartmental analysis, and safety was recorded. An integrated, physiologically based PK model built in Simcyp ® provided additional insight into this interaction. Drug-drug interaction intensity was measured by the ratio of systemic exposure (area under plasma concentration-time curve [AUC] ) of perampanel in the presence or absence of concomitant ketoconazole.
Results: Single oral doses of 1 mg perampanel and once-daily oral doses of ketoconazole 400 mg were safe and well tolerated. Maximum perampanel plasma concentration (C max ) and time to C max showed no apparent differences when perampanel was administered alone versus with ketoconazole. Ketoconazole co-administration with resulted in an approximate 20% increase in perampanel AUC (P<0.001). This increase, although statistically significant, was a <2.0-fold AUC change and alone would suggest a modest effect of ketoconazole. To further explore these results, DDI simulations were performed to query the findings and test additional study conditions. Using the actual trial conditions of Study 005, the simulations also predicted an AUC ratio increase <2-fold, providing verification of the simulation assumptions and the modest effect of ketoconazole for 10 days. Simulations further suggested that an interaction effect of ketoconazole on perampanel exposure (>2-fold) of potential clinical significance could be predicted when using larger doses of ketoconazole (e.g., 200 mg every 6 hours) coadministered for a greater time period (e.g., 30 days), with AUC ratio as high as 3.36. Additionally, simulations suggested that a significant interaction with co-administration of perampanel and an inhibitor more potent than ketoconazole (such as itraconazole) could not be ruled out.
Conclusions:
Selecting an appropriate study design is critical to fully characterize the PK interaction for drugs such as perampanel that have a long t 1/2 . Although a negligible effect on perampanel PK was observed following co-administration of ketoconazole 400 mg/day for 10 days, this is likely due in part to the relatively brief co-administration period of ketoconazole and perampanel (<3 times the t 1/2 of perampanel). While short-term administration of a CYP3A inhibitor may not significantly increase perampanel exposure, such increases may be expected following chronic and larger dosing or with a more potent inhibitor.
ABBREVIATIONS
AED, antiepileptic drug; ANOVA, analysis of variance; AUC, area under the concentration-time curve;
AUC 0-inf , area under the concentration-time curve extrapolated to infinity; BID, twice per day; CI, confidence interval; CL int , intrinsic retrograde-calculated clearance; C max , maximum plasma concentration;
C min , trough concentration; DDI, drug-drug interaction; ECG, electrocardiogram; FDA, US Food and Drug
INTRODUCTION
Perampanel is an orally active, noncompetitive, selective AMPA receptor antagonist that is approved as adjunctive therapy for the treatment of both partial seizures, with or without secondarily generalized seizures, and primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy aged 12 years and older (Fycompa Prescribing Information, 2016; Rogawski and Hanada, 2013) .
Perampanel is a low-extraction ratio drug, meaning that it has minimal first-pass metabolism (Fycompa Prescribing Information, 2016) . Perampanel does not appear to be a substrate for P-glycoprotein (Patsalos, 2015) . Following oral administration, absorption of perampanel is rapid and almost complete, with peak plasma concentrations being achieved in approximately 1 hour (Franco et al., 2013) .
Perampanel is extensively protein bound (95-96%), primarily to albumin and α1-acid glycoprotein (Fycompa Prescribing Information, 2016; Patsalos, 2015) .
Both absorption and elimination pharmacokinetics (PK) of perampanel are linear, predictable and essentially complete over the clinically relevant dosing range of 2-12 mg/day (Patsalos, 2015) . In vitro studies demonstrate that perampanel is not a substrate for multidrug efflux transporters including Pglycoprotein, BCRP, or human anion transporters (OAT1-4) (Patsalos, 2015) . Perampanel is extensively metabolized (>90%) via hepatic oxidation and sequential glucuronidation of inactive metabolites (Patsalos, 2015) . Specifically, the principal enzymes involved are cytochrome P4503A4 (CYP3A4) and/or CYP3A5 (Patsalos, 2015) . Although CYP3A-mediated metabolism of this agent is the primary route of elimination, perampanel apparent oral clearance is relatively slow. Population PK analyses from the perampanel Phase 1 program, which included pooling data from >20 separate studies, determined that the mean elimination half-life (t 1/2 ) is approximately 105 hours. Based on this, if one accepts that steadystate is achieved in 4-5 half-lives, then steady-state would require approximately16-20 days of repeat dosing.
It is well recognized that understanding PK interactions both between AEDs and between AEDs and non-AED medications is important in optimizing therapy in patients with epilepsy (Zaccara and Perucca, 2014) .
Based on in vitro and population PK data, it would not be anticipated that perampanel will itself perpetrate significant PK interactions (Patsalos, 2015) . However, given its extensive metabolism via CYP3A, it is well documented that the oral clearance of perampanel can be markedly affected by enzyme-inducing AEDs such as phenytoin, carbamazepine, and oxcarbazepine (Fycompa Prescribing Information, 2016; Gidal et al., 2013; Gidal et al., 2015) . Indeed, these three inducers may increase perampanel clearance by two-to threefold (Gidal et al., 2013) .
Although the impact of enzyme induction on perampanel plasma concentrations and expected therapeutic response are well known (Gidal et al., 2015) , the potential effect of enzyme inhibition on perampanel is not as well understood. Conceptually, because its elimination is largely controlled by CYP3A-mediated metabolism, inhibition of CYP3A may result in an increase in the systemic exposure of perampanel, possibly leading to adverse effects. Indeed, in vitro studies using human liver microsomes revealed that the CYP3A4 0.3μM of ketoconazole inhibited 60-65% of the metabolite formation of M1
(the most abundant metabolite formed), M3, M4, and M19. Similarly, ketoconazole also inhibited the in vitro formation of M6, M7, and M8 (Data on file, Eisai, Study B07001). The formation of all perampanel metabolites was inhibited by ketoconazole in a concentration-dependent manner. Curiously, however, a dedicated drug interaction study conducted in healthy volunteers using this same strong CYP3A4 inhibitor resulted in only a negligible increase in perampanel exposure. Clearly, given these seemingly conflicting findings, a more complete understanding of the potential for inhibitory interactions is important in optimizing the clinical use of this AED.
The objectives of this manuscript are two-fold. First, we describe the results of a standard, Phase 1 drugdrug interaction (DDI) study that was conducted in healthy subjects using the potent CYP3A inhibitor ketoconazole (U.S. Department of Health and Services, 2012) . Second, we further explore and discuss the larger clinical implications of this potential DDI using in silico predictions as a way to reconcile the healthy volunteer data with in vitro metabolic findings.
METHODS

Phase I Drug-Drug Interaction Study
Subjects and Design
This open-label, randomized, two-period, two-treatment, two-way crossover, DDI study included 26 healthy male subjects, aged 18 to 45 years. Subjects were randomized to one of two study groups (Group A or B), each consisting of 13 subjects (Figure 1) . Each study group participated in two treatment periods.
During Period 1, subjects in Group A received oral ketoconazole 400 mg once daily from Day 1 to Day 10 and a single oral dose of perampanel 1 mg on Day 3; subjects in Group B received a single oral dose of perampanel 1 mg on Day 1. During Period 2, this treatment scheme was reversed: subjects in Group A received a single oral dose of perampanel 1 mg on Day 1, and subjects in Group B received oral ketoconazole 400 mg once daily from Day 1 to Day 10 and a single oral dose of perampanel 1 mg on Day 3. Ketoconazole was therefore co-administered for 8 days following perampanel administration in this study. To reduce carryover, there was a washout of at least 10 days between treatment periods. Subjects fasted prior to any perampanel administration. On the days when only ketoconazole was administered, subjects were dosed 15 minutes after the start of breakfast.
Safety and tolerability were assessed by vital signs, 12-lead electrocardiogram (ECG), physical examination, adverse events, and laboratory safety variables (from blood and urine samples).
All subjects provided informed, written consent to participate in the study. The study was conducted in accordance with the Declaration of Helsinki (Edinburgh, Scotland, October 2000), the International
Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guideline for
Good Clinical Practice, and Hammersmith Medicines Research Standard Operating Procedures.
Pharmacokinetic Parameters, Safety, and Statistical Analysis
Blood samples to assess perampanel PK were drawn predose and up to 288 hours postdose (Figure 1 ).
Blood samples for ketoconazole PK were drawn predose on Days 2, 3, and 4 (Period 1 for Group A and
Period 2 for Group B) to assess whether steady-state levels had been achieved at the time of perampanel dosing on Day 3.
Pharmacokinetic parameters were calculated by noncompartmental analysis and included maximum plasma concentration (C max ), time to C max (t max ), and area under the concentration-time curve extrapolated to infinity (AUC 0-inf ) for perampanel, and trough concentration (C min ) for ketoconazole.
C max and AUC 0-inf were logarithmically transformed and subjected to analysis of variance (ANOVA). Based on the residual variation of ANOVA, 90% confidence intervals (CIs) for the ratio of geometric means were calculated for PK parameters in each treatment condition. Using perampanel with ketoconazole as the test treatment and perampanel without ketoconazole as a reference treatment, absence of a drug interaction was concluded if the 90% CI of the log ratio (test treatment:reference treatment) fell entirely within the range of 80% to 125%. t max values were compared using the 90% CI of the median of the difference between test and reference treatments (perampanel with ketoconazole minus perampanel without ketoconazole), calculated from the Wilcoxon signed-rank test. To test for steady-state concentrations, an ANOVA of C min for ketoconazole was performed on data that were log-transformed (log base 10) before analysis, with effects for subject, period, and day. The day on which steady-state concentrations were achieved was determined by contrast analysis of the ANOVA results. Numerical data were summarized using means and/or medians and other descriptive statistics, according to the type and distribution of the data.
Physiologically Based Pharmacokinetic Modeling and Simulation
To explore and gain a more complete understanding of the effects of ketoconazole on perampanel PK, in silico simulations based on physiologically based PK (PBPK) modeling were performed. This approach has been shown useful in predicting drug PK and potential drug interactions Zhao et al., 2012) . Simcyp ® version 11 software (Simcyp Ltd, Sheffield, UK, http://www.simcyp.com), which is described in detail elsewhere (Jamei et al., 2009) , was used to develop the PBPK model. In addition, it was assumed that for perampanel, CYP3A was the only metabolic route of elimination; renal excretion was included as a minor contributor. Various perampanel in vitro and in vivo physiologic parameters, such as renal clearance, CYP3A inhibition measures, and measures for transporters interaction, were incorporated into the model (Supplementary Material Table 1 ). The final model included an intrinsic retrogradecalculated clearance (CL int ) value from the observed total clearance of perampanel in clinical studies, yielding AUC ratios that were in better agreement with the observed DDI study data as compared to the model using the CL int value from in vitro recombinant enzyme systems. All simulations were performed assuming 100 subjects (10 trials of 10 subjects each), using a "healthy volunteer" population with a 1:1 male to female ratio. It was assumed that fasting doses were administered with 250 mL of water for all simulations.
The model's overall predictive performance was evaluated in three steps. First, the mean simulated, predicted concentration-time profile of a single, oral 2 mg perampanel dose was plotted versus observed concentration data for perampanel compiled from the existing Phase I study database for population PK analysis. Once agreement was achieved between predicted and observed perampanel concentrations, additional simulations were performed for perampanel doses of 1 and 8 mg. The second step of the performance evaluation consisted of simulating the doses and dose regimens of the DDI trial with ketoconazole. In addition to a series of simulations performed assessing the effect of ketoconazole on perampanel exposure, a separate simulation of the effect of carbamazepine was completed. exposure to a CYP3A inhibitor with a longer elimination t 1/2 than that of ketoconazole (itraconazole).
RESULTS
Phase I Drug-Drug Interaction Study
The 26 subjects included in this study were all male and mostly white (92%; 24/26), with a median age of For all subjects, vital signs and the results of physical examinations were within the normal range. All subjects complied with the study protocol and completed the study.
Mean perampanel plasma concentrations over time were similar for perampanel 1 mg administered alone and perampanel 1 mg administered with ketoconazole 400 mg (Figure 2) . Moreover, no apparent differences emerged in C max and t max when perampanel was administered alone or with ketoconazole ( The bioequivalence ratios for perampanel alone and with ketoconazole demonstrated that the 90% CI for C max and t 1/2 fell within the predefined bioequivalence range of 80% to 125% ( Table 2 ). The 90% upper CI for AUC 0-inf (128.5%) was slightly higher than the upper limit for bioequivalence (125%). The median difference in t max for perampanel with versus without ketoconazole was 0.25 hours (90% CI: 0-0.5 h). The geometric mean C min values for ketoconazole on Days 2, 3, and 4 were 87.9, 284.3, and 391.3 ng/mL, respectively.
There was no evidence that adverse events were more frequent or more severe after perampanel plus ketoconazole than after perampanel alone. The most common adverse event after perampanel 1 mg was headache (n=8 subjects). Only two adverse events were reported after dosing with ketoconazole (pain and lightheaded). Overall, none of the laboratory values showed changes that were clinically significant.
There were no significant changes in any vital signs or 12-lead ECGs during the study.
PBPK Modeling and Simulation
Given that perampanel is metabolized almost exclusively via CYP3A, the outcome of the Phase I DDI study was unexpected, as the known effect of the strong CYP3A inhibitor ketoconazole is to increase exposure of CYP3A substrates (U.S. Department of Health and Services, 2012). Therefore, the result was further examined and additional study conditions were explored via PBPK modeling and simulation.
Performance Evaluation
The Simcyp ® PBPK model adequately predicted the perampanel in vivo PK profile by accurately predicting the bioavailability and concentration-time profile of perampanel (Figure 3 ).
DDI simulations with once-daily ketoconazole 400 mg assessed under the conditions of the study resulted in AUC ratios with versus without ketoconazole that, while not in numerical agreement with the observed ratio in the DDI study (1.59 vs 1.20), are within the acceptable error range for the study, as calculated according to Guest et al. (2011) These results confirmed that a relatively negligible effect of ketoconazole on perampanel exposure under the conditions tested in the study could be expected (Figure 4) . The results of the sensitivity analysis indicate that renal clearance, polar surface area (<100 Å), fraction unbound in microsomal preparation (fu mic ), and blood-to-plasma ratio would have a small impact on the predicted PK parameters of perampanel (Supplementary Material Table 1 ). Taken together, these results suggest that the PBPK model built using Simcyp ® is adequate to further explore predictions of DDI between perampanel and ketoconazole. Dosing perampanel at the time of maximum ketoconazole concentration, i.e., administering perampanel 1 hour after ketoconazole dosing, was predicted to have no additional effect on the AUC ratio. The predicted AUC ratio of with/without ketoconazole for the 1 hour pre-administration was 1.59 (95% CI:
Additional Simcyp
1.48-1.70), which was the same as the ratio for simultaneous administration of 400 mg QD ketoconazole with 1 mg perampanel.
The predicted AUC ratio of with/without ketoconazole (400 mg QD for 10 days) with the maximum clinical dose of perampanel (12 mg single dose on Day 3) was 1.58 (95% CI: 1.47-1.69). This value was similar to that predicted for a perampanel dose of 1 mg, suggesting that the DDI impact of ketoconazole on perampanel exposure is consistent across perampanel doses of 1 to 12 mg. Additional model scenarios were examined to further elucidate the effect of ketoconazole dose, dose regimen, and length of treatment on predicted perampanel exposure at a dose of 1 mg on Day 3. In order to observe an interaction of greater magnitude (AUC ratio increases >2.0), larger/more frequent doses of ketoconazole given for a longer time period were necessary ( Table 3) . Because of the length of the simulations, the number of subjects considered was reduced to 50 (5 trials of 10 subjects each). The 30-day, simulation-predicted AUC ratios of with/without ketoconazole were again higher than those in the 15-day simulations. An intensive (supratherapeutic) ketoconazole regimen (400 mg every 2 h for 15 days), which is predicted to almost completely inhibit both intestinal and hepatic CYP3A intrinsic clearance, yielded a mean AUC ratio of 2.24 (95% CI: 1.93-2.59), 4.2% higher than the AUC ratio predicted for ketoconazole 200 mg BID. The 30-day predicted AUC ratio with ketoconazole 200 mg every 6 h was 3.36 (95% CI: 2.82-4.01) ( Table 3 ). This represents a significant increase of >2-fold in the AUC ratio over that seen with ketoconazole 200 mg BID for 10 days (1.74; 95% CI: 1.61-1.88).
Taken together, these results suggest that development of a significant increase in perampanel exposure over time following chronic dosing can be expected and that the duration of the study relative to the t 1/2 of the substrate plays a significant role in the predicted AUC ratio.
DISCUSSION
Based on the results from the clinical DDI study, our observations suggest that short-term coadministration of a potent CYP3A inhibitor such as ketoconazole given 400 mg once daily for 10 days is unlikely to result in a clinically meaningful interaction with perampanel. At first glance, these findings might seem counterintuitive, given the dependence of perampanel elimination on CYP3A-mediated metabolism and the known effects of ketoconazole, a potent CYP3A inhibitor, to increase exposure of CYP3A substrates. To improve understanding of these seemingly unexpected findings, it is important to understand the mechanisms underlying this type of inhibitor interaction and its relationship to a molecule such as perampanel.
Until recently, ketoconazole has been used extensively as a standard inhibitor of CYP3A, and it has been widely considered the standard by both drug developers and regulatory agencies (Greenblatt et al., 2011) .
The traditional ketoconazole regimen used for studies was 400 mg daily for 2-5 days (Stoch et al., 2009;  U.S. Department of Health and Services, 2012), although adjustments should be made based on the halflife of the CYP3A substrate under investigation.
Ketoconazole is considered to be a competitive inhibitor. As such, the inhibitory effect of ketoconazole is immediate, and begins following oral absorption. Unlike drugs displaying mechanism-based inhibition, the effect of ketoconazole would be expected to dissipate as soon as ketoconazole concentrations decline. It is for this reason that typical DDI studies are designed to continue ketoconazole dosing to correspond to the t ½ of the substrate drug. The triazole antifungal drugs including ketoconazole and itraconazole are considered "strong" inhibitors of a variety of CYP3A substrates (Nizoral Prescribing Information, 2011; Sporanox Data Sheet, 2013) , leading to the assumption that these drugs can affect all CYP3A substrates equally, with inhibitory effects resulting in exposure increases of substrate drugs that can exceed 5-fold.
Indeed, inhibitory concentrations (IC50) for substrates such as midazolam and testosterone are in the low nanomolar range for ketoconazole (Greenblatt et al., 2011) . It may not be correct, however, to oversimplify these experimental observations and conclude that ketoconazole will affect all CYP3A
substrates equally. Review of in vitro studies has demonstrated a marked degree of variability in the relative potency of ketoconazole-mediated inhibition, not only between substrates, but even within a single substrate, when one looks at different metabolic pathways. As a class, the triazole antifungal drugs do not appear to display mechanism-based inactivation of CYP3A isozymes, where a CYP450 reaction results in the formation of a reactive metabolite that covalently binds to the enzyme and irreversibly inhibits its activity (Greenblatt et al., 2011; Kamel and Harriman, 2013) . On an individual basis, genetic expression of CYP3A4 and CYP3A5 may influence the intensity of drug-drug inhibitory interactions (Akiyoshi et al., 2013; Yamazaki et al., 2010) . In addition to these issues, it is crucial to consider the PK properties of both the inhibitor and the object drug, such as clobazam or other similar AEDs (Walzer et al., 2012) , or in this case, perampanel.
Ketoconazole has a biphasic t 1/2 with rapid elimination of approximately 2 hours during the first 10 hours and a slower elimination of approximately 8 hours thereafter (Nizoral Prescribing Information, 2011), with peak plasma concentrations occurring in about 2 hours. Based on in vitro estimates with other CYP3A drugs such as midazolam, one would expect sufficient ketoconazole remaining at 12 hours post-dosing to effectively inhibit CYP3A-mediated metabolism of a drug with a relatively short t 1/2 such as midazolam (1-4 hours). Importantly, midazolam also has relatively low oral bioavailability (~ 50%), suggesting that it undergoes substantial presystemic clearance in intestinal epithelial tissue (Riss et al., 2008) ; thus, the overall effect of ketoconazole to increase exposure of substrates such as midazolam results from inhibition of first-pass clearance in addition to inhibition of systemic clearance.
In contrast, perampanel is a low-extraction ratio drug that has essentially 100% oral bioavailability, indicating very low presystemic first-pass metabolism (Patsalos, 2015) . This drug also has a particularly long elimination t 1/2 of about 105 hours (Fycompa Prescribing Information, 2016) . It is therefore not at all surprising that co-administration of ketoconazole at typical clinical doses for 8 days did not result in a marked increase in perampanel exposure or reduction in clearance, since as the bioavailability of a drug increases, it becomes less sensitive to the inhibition of presystemic metabolism seen with ketoconazole (Boxenbaum, 1999; Zhao et al., 2009) . In a series of simulations, Zhao and colleagues noted that using once-daily dosing regimens of ketoconazole (as is typically employed in DDI screening studies) is likely to provide maximal inhibition for only a subset of drugs, such as those demonstrating low oral bioavailability and short elimination half-lives (Zhao et al., 2009 ). For drugs with elimination half-lives greater than that of ketoconazole, multiple daily dosing regimens are needed. It follows then, that in the case of perampanel, a drug with an elimination t 1/2 that is much longer than that of ketoconazole, demonstration of inhibition would require both a larger daily dose and more prolonged dosing of ketoconazole in order to cover the entire elimination phase of perampanel, including the anticipated prolongation of half-life of the substrate drug in the presence of ketoconazole. Of note, in the dedicated human DDI study reported here, a perampanel elimination t 1/2 of about 52 hours was calculated when perampanel was given alone.
This t 1/2 is shorter than reported for later Phase 1 PK studies subsequently conducted during perampanel clinical development. This may be attributable to later study designs including PK sampling for 21 days, coupled with doses higher than the 1 mg dose which was used in this DDI study, thus allowing for the perampanel half-life of 105 hours to be confirmed. Nonetheless, even assuming a perampanel t 1/2 of 52 hours in the absence of ketoconazole, one would still need to administer ketoconazole for at least 11-15 days in order to capture the full extent of the inhibitor on perampanel systemic exposure, including the expected effect of ketoconazole to prolong the half-life of perampanel. Simply stated, using standard study designs is likely to underestimate the drug-interaction potential of drugs like perampanel characterized by long half-lives by an inhibitor like ketoconazole (Han et al., 2013; Zhao et al., 2009 ). Based on the observations from the simulations, it can be predicted that dosing of ketoconazole beyond 8 days would be required to detect a clinically meaningful interaction with perampanel. Short-term administration of a potent CYP3A inhibitor may not result in significant increases in perampanel exposure, but over time, development of such increases following chronic dosing can be expected. Knowledge of the effect of chronic dosing on perampanel exposure is vital in order to understand clinical effects (efficacy and/or safety) and for the clinician to better guide and individualize treatment.
To confirm this, PBPK model simulations were performed for both ketoconazole and itraconazole, a triazole inhibitor with a much longer t 1/2 . Consistent with the concepts presented previously, whether one detects a meaningful interaction depends largely on the design of the study. Using typical labeled doses of ketoconazole for a relatively short period of time does not result in significant changes in perampanel exposure. However, our simulations also clearly suggest that increasing both the chronic dose and the duration of ketoconazole treatment (30 days) would result in a significant and clinically important increase in perampanel systemic exposure. For example, the simulations show that ketoconazole at doses of 400 mg/day (either QD or BID) can increase perampanel concentrations above twofold. Similarly, simulations modeling longer treatment duration of itraconazole also resulted in a significant increase in perampanel AUC. Moreover, our model also suggests that the timing of administration of an inhibitor (i.e., ketoconazole and perampanel given either together or at separate time points) is not likely to influence the magnitude of this interaction, an observation that is entirely consistent with the lack of first-pass metabolism and high bioavailability of perampanel. This helps explain the surprisingly small effect of ketoconazole observed in the study summarized above. In fact, the simulations show that ketoconazole can produce a marked effect, as expected for a substrate that is primarily eliminated via CYP3A
metabolism. In the case of co-administration with perampanel, however, ketoconazole exerts such influence only under conditions of intensive, long-term dosing.
CONCLUSIONS
The results of the Phase I study in healthy men show that a single, 1-mg dose of perampanel and 400 mg of ketoconazole taken once a day for 10 days produced a small increase in perampanel AUC. Simulations using the Simcyp ® PBPK model support the conclusion of the Phase I study that ketoconazole, when tested under the typically employed DDI testing paradigm, has a relatively small effect on perampanel exposure.
Clearly, there are pragmatic clinical questions that remain. For example, these studies were not designed to explore the impact of multiple CYP3A4 inhibitors with differing mechanisms (e.g., competitive + mechanism-based inhibition), nor were patients who were concomitantly receiving a CYP3A4 inducer included. How should clinicians use these observations? While it is important to recognize that clinically important PK interactions are likely for any drug metabolized primarily by CYP3A, our observations clearly demonstrate that both the detection and magnitude of potential interactions depend on how the study is designed. In the case of perampanel, short-term co-administration of a known CYP3A inhibitor such as ketoconazole is likely to result in modest changes in perampanel exposure. However, a greater interaction can be expected with long-term, intensive exposure or with an inhibitor more potent than ketoconazole. This study was funded by Eisai Inc.
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FIGURE LEGENDS
PER=perampanel. AUC=area under the concentration-time curve; BID=twice daily; CI=confidence interval; DDI=drug-drug interaction; PER=perampanel; q6h=every 6 hours; q2h=every 2 hours; QD=once daily.
